Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
The event will include an exhibition and sector-wise sessions for two days with participation by officials from the Ministry of Commerce, export promotion councils and members of the industry
_256_384.jpg)
As of June 30, 2021, 267 out of a total of 427 SEZs approved by the government are operational
Drug formulations and biologics make impressive gains
The company has predominantly built a portfolio into veterinary products
The Department of Pharmaceuticals launched the PLI scheme for promoting domestic manufacturing of bulk drugs, with a financial outlay of Rs. 6,940 crore across 53 APIs over 6 years
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
Subscribe To Our Newsletter & Stay Updated
